Siegfried Kasper1, Christian Bancher2, Anne Eckert3, Hans Förstl4, Lutz Frölich5, Jakub Hort6,7, Amos D Korczyn8, Reto W Kressig9, Oleg Levin10, María Sagrario Manzano Palomo11. 1. Center for Brain Research, Medical University of Vienna, Vienna, Austria. 2. Department of Neurology/Neurological Rehabilitation, Landesklinikum Horn-Allentsteig, Horn, Austria. 3. Neurobiology Lab for Brain Aging and Mental Health, Transfaculty Research Platform Molecular & Cognitive Neuroscience (MCN), University of Basel, Psychiatric University Clinics Basel, Basel, Switzerland. 4. Clinic and Polyclinic for Psychiatry and Psychotherapy, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany. 5. Department of Gerontopsychiatry, Central Institute of Mental Health Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. 6. Department of Neurology, Charles University, 2nd Medical Faculty, and Motol University Hospital, Prague, Czech Republic. 7. International Clinical Research Centre, Brno, Czechia. 8. Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. 9. University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Basel, Switzerland. 10. Russian Medical Academy of Continuous Professional Education, Moscow, Russia. 11. Neurology Department, Hospital Infanta Leonor, Madrid, Spain.
Abstract
Objectives: To review available evidence of pharmacological and non-pharmacological treatment for MCI and analyse information and limitations in national and international guidelines. Methods: Experts from several European countries conducted a qualitative review of the literature on MCI and treatments for MCI, as well as respective chapters in national and international guidelines on dementia/MCI. Psychotherapeutic/psychosocial treatments were excluded from the review. Results: Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible. MCI can be identified in a primary care setting. Further corroboration and differential diagnosis should be done at specialist level. Mixed pathologies are the rule in MCI, thus a multi-target treatment approach is a rational strategy. Promising evidence has been generated for multi-domain interventions. Limited evidence is available for different pharmacological classes that have been investigated in MCI clinical trials (e.g. acetylcholinesterase inhibitors). EGb 761® improved symptoms in some clinical trials; it is the only pharmacological treatment recommended in existing guidelines for the symptomatic treatment of MCI.Conclusions: MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI. However, more needs to be done, especially at an international level.
Objectives: To review available evidence of pharmacological and non-pharmacological treatment for MCI and analyse information and limitations in national and international guidelines. Methods: Experts from several European countries conducted a qualitative review of the literature on MCI and treatments for MCI, as well as respective chapters in national and international guidelines on dementia/MCI. Psychotherapeutic/psychosocial treatments were excluded from the review. Results: Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible. MCI can be identified in a primary care setting. Further corroboration and differential diagnosis should be done at specialist level. Mixed pathologies are the rule in MCI, thus a multi-target treatment approach is a rational strategy. Promising evidence has been generated for multi-domain interventions. Limited evidence is available for different pharmacological classes that have been investigated in MCI clinical trials (e.g. acetylcholinesterase inhibitors). EGb 761® improved symptoms in some clinical trials; it is the only pharmacological treatment recommended in existing guidelines for the symptomatic treatment of MCI.Conclusions: MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI. However, more needs to be done, especially at an international level.
Authors: Ricardo Bruña; David López-Sanz; Fernando Maestú; Ann D Cohen; Anto Bagic; Ted Huppert; Tae Kim; Rebecca E Roush; Betz Snitz; James T Becker Journal: Clin EEG Neurosci Date: 2022-02-21 Impact factor: 2.046
Authors: Lucrezia Hausner; Lutz Frölich; Christine A F von Arnim; Jens Bohlken; Richard Dodel; Markus Otto; Michael Rapp; Jörg Schulz; Tilmann Supprian; M Axel Wollmer; Frank Jessen Journal: Nervenarzt Date: 2020-10-06 Impact factor: 1.214